Royan Institute is a renowned center committed to multidisciplinary, campus-wide, integration and collaboration of academic and medical personnel for understanding male/ female infertility, embryo development, stem cell biology, and biotechnology. Royan Institute provides comprehensive services for the infertility treatment, regenerative medicine/cell therapy, production of recombinant proteins and development of biological products.
On June 14, 2026, Royan Institute, recognized as one of the country's foremost pioneering institutions in the fields of life sciences, stem cell research, and advanced medical technologies, hosted a delegation of members from the Health and Medical Services Commission of the Islamic Consultative Assembly.
Knowledge-based product WhartoCell, developed on the basis of umbilical cord–derived stem cells and indigenous technology, has received authorization from the Food and Drug Administration for the treatment of osteoarthritis, with the aim of reducing inflammation and promoting cartilage regeneration.
